1 / 6

Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE

Phase 3. Treatment Experienced. Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE. Vierling JM, et al. J Hepatol . 2013;Dec 19 [ Epub ahead of print]. Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE Study: Features.

jera
Download Presentation

Boceprevir for Patients with Prior Failure to PEG + RIB PROVIDE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Phase 3 TreatmentExperienced Boceprevir for Patients with Prior Failure to PEG + RIBPROVIDE Vierling JM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].

  2. Boceprevir for Patients with Prior Failure to PEG + RIBPROVIDE Study: Features Drug DosingBoceprevir = 800 mg three times dailyPeginterferon alfa-2b = 1.5 µg/kg once weeklyRibavirin = 600-1400 mg/day (based on weight) Source: VierlingJM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].

  3. Boceprevir for Patients with Prior Failure to PEG + RIBPROVIDE Study: Treatment Regimens Week 0 4 8 12 24 36 44 48 Patients who enrolled within 2 weeks after ending/completing previous treatment with PR B44 PR44 Boceprevir Peginterferon + Ribavirin Patients who enrolled ≥ 2 weeks after ending/completing their previous treatment with PR Boceprevir B44PR48 Peginterferon + Ribavirin Lead In Source: Vierling JM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].

  4. Boceprevir for Patients with Prior Failure to PEG + RIBPROVIDE Study: Results PROVIDE: SVR 24 by Prior Response (mITT) 106/164 20/49 57/85 27/28 SVR = Sustained Virologic Response; mITT = modfied intent to treat analysis Source: Vierling JM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].

  5. Boceprevir for Patients with Prior Failure to PEG + RIBPROVIDE Study: Conclusions Source: Vierling JM, et al. J Hepatol. 2013;Dec 19 [Epub ahead of print].

  6. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related